Zydus receives USFDA nod for 2 products
Drug firm Zydus Cadila Thursday said it has received approvals from the US health regulator for its Phytonadione tablets and Colchicine tablets.
The company has received final approval from the United States Food and Drug Adminstration (USFDA) to market generic Phytonadione tablets USP in the strength of 5 mg, Zydus Cadila said in a statement.
The product is used to treat and prevent low levels of blood clotting factors that the body naturally produces when caused by vitamin K deficiency or interference with vitamin K activity, it added.
The group also received the final approval for generic Colchicine tablets USP, 0.6 mg, Zydus Cadila said
Disclaimer: No Business Standard Journalist was involved in creation of this content